Total neoadjuvant therapy in rectal cancer: the evidence and expectations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001090" target="_blank" >RIV/00064190:_____/23:10001090 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/23:10470658 RIV/00216208:11110/23:10470658

Výsledek na webu

<a href="https://doi.org/10.1016/j.critrevonc.2023.104196" target="_blank" >https://doi.org/10.1016/j.critrevonc.2023.104196</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.critrevonc.2023.104196" target="_blank" >10.1016/j.critrevonc.2023.104196</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Total neoadjuvant therapy in rectal cancer: the evidence and expectations

Popis výsledku v původním jazyce

Current management of locally advanced rectal cancer achieves high cure rates, distant metastatic spread being the main cause of patients&apos; death. Total neoadjuvant therapy (TNT) employs (chemo)radiotherapy and combined chemotherapy prior to surgery to improve the treatment outcomes. TNT has been shown to reduce significantly distant metastases, increase disease-free survival by 5 - 10% in 3 years, and finally also overall survival (ALMOST EQUAL TO 5% in 7 years). It proved to double the rate of pathologic complete responses, making it an attractive strategy for non-operative management to avoid permanent colostomy in patients with distal tumors. In addition, it endorses adherence to the therapy due to better tolerance and, potentially, shortens its overall duration. A number of questions related to TNT remain currently unresolved including the indications, preferred radiotherapy and chemotherapy regimens, their sequence, timing of surgery, and role of adjuvant therapy. A stratified approach may be the optimal way to go. (C) 2023 The Authors

Název v anglickém jazyce

Total neoadjuvant therapy in rectal cancer: the evidence and expectations

Popis výsledku anglicky

Current management of locally advanced rectal cancer achieves high cure rates, distant metastatic spread being the main cause of patients&apos; death. Total neoadjuvant therapy (TNT) employs (chemo)radiotherapy and combined chemotherapy prior to surgery to improve the treatment outcomes. TNT has been shown to reduce significantly distant metastases, increase disease-free survival by 5 - 10% in 3 years, and finally also overall survival (ALMOST EQUAL TO 5% in 7 years). It proved to double the rate of pathologic complete responses, making it an attractive strategy for non-operative management to avoid permanent colostomy in patients with distal tumors. In addition, it endorses adherence to the therapy due to better tolerance and, potentially, shortens its overall duration. A number of questions related to TNT remain currently unresolved including the indications, preferred radiotherapy and chemotherapy regimens, their sequence, timing of surgery, and role of adjuvant therapy. A stratified approach may be the optimal way to go. (C) 2023 The Authors

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

ISSN

1040-8428

e-ISSN

1879-0461

Svazek periodika

192

Číslo periodika v rámci svazku

12/2023

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

001111492300001

EID výsledku v databázi Scopus

2-s2.0-85176232917